A first-in-human study of the anti-α5β1 integrin monoclonal antibody PF-04605412 administered intravenously to patients with advanced solid tumors

PURPOSE: A first-in-human clinical trial of a fully human, Fc-engineered IgG1 monoclonal antibody targeting integrin α5β1 was conducted to evaluate tolerability, maximum tolerated dose, pharmacokinetics, pharmacodynamics and preliminary anti-tumor activity. METHODS: Escalating doses of PF-04605412 w...

Descripción completa

Detalles Bibliográficos
Autores principales: Mateo, J., Berlin, J., de Bono, J. S., Cohen, R. B., Keedy, V., Mugundu, G., Zhang, Lianglin, Abbattista, A., Davis, C., Gallo Stampino, C., Borghaei, H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2014
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4209234/
https://www.ncbi.nlm.nih.gov/pubmed/25212537
http://dx.doi.org/10.1007/s00280-014-2576-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4209234/
https://www.ncbi.nlm.nih.gov/pubmed/25212537
http://dx.doi.org/10.1007/s00280-014-2576-8

Ejemplares similares